Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Radotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 12/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 11/20 | 0.83 |
| ▸ | LDLR | P01130 | 8/20 | 0.83 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 0.83 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.83 |
| ▸ | LCK | P06239 | 4/20 | 0.83 |
| ▸ | LYN | P07948 | 4/20 | 0.83 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.83 |
| ▸ | FLT3 | P36888 | 4/20 | 0.83 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.83 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.83 |
| ▸ | SRC | P12931 | 2/20 | 0.83 |
| ▸ | RAF1 | P04049 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radotinib SCHEMBL29381661 | 1.00 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| Radotinib SCHEMBL29366343 | 1.00 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| Radotinib SCHEMBL30002961 | 0.99 | ABL1 (0.99) | ABL1BCRADORA3NR1I2PTGS1 | |
| Radotinib SCHEMBL15285797 | 0.99 | ABL1 (0.99) | ABL1BCRADORA3NR1I2PTGS1 | |
| Radotinib SCHEMBL15318848 | 0.99 | ABL1 (0.97) | ABL1BCRADORA3NR1I2PTGS1 | |
| SCHEMBL3945090 | 0.92 | ABL1 (0.85) | ABL1BCRADORA3NR1I2PTGS1 | |
| Nilotinib SCHEMBL29366964 | 0.91 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| Nilotinib SCHEMBL29580067 | 0.91 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| Nilotinib SCHEMBL7901 | 0.91 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| SCHEMBL20502603 | 0.91 | KIT (0.85) | ABL1BCRADORA3NR1I2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| EP-1922309-B1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | IL YANG PHARM CO LTD (KR) | 2014-05-21 | — | — | EP | claimed |
| WO-2013147414-A1 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF | IL-YANG PHARM. CO., LTD (KR) | 2013-10-03 | — | — | WO | claimed |
| US-7501424-B2 | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | IL-YANG PHARM. CO., LTD. (KR) | 2009-03-10 | — | — | US | claimed |
| US-20080096899-A1 | N-Phenyl-2-Pyrimidine-Amine Derivatives and Process for the Preparation Thereof | IL-YANG PHARM. CO., LTD. (KR) | 2008-04-24 | — | — | US | claimed |
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | disclosed |
| EP-1922309-B1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | IL YANG PHARM CO LTD (KR) | 2014-05-21 | — | — | EP | disclosed |
| WO-2013147414-A1 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF | IL-YANG PHARM. CO., LTD (KR) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013147414-A1 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF | IL-YANG PHARM. CO., LTD (KR) | 2013-10-03 | — | — | WO | disclosed |
| WO-2010018895-A1 | PROCESS FOR THE PREPARATION OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | IL-YANG PHARM. CO., LTD. (KR) | 2010-02-18 | — | — | WO | disclosed |
| US-7501424-B2 | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | IL-YANG PHARM. CO., LTD. (KR) | 2009-03-10 | — | — | US | disclosed |
| US-20080096899-A1 | N-Phenyl-2-Pyrimidine-Amine Derivatives and Process for the Preparation Thereof | IL-YANG PHARM. CO., LTD. (KR) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096899-A1 | N-Phenyl-2-Pyrimidine-Amine Derivatives and Process for the Preparation Thereof | ITPA, TYMP, THPO | ABL1 451/4885BCR 990/4885ADORA3 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.